{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:07:27Z","timestamp":1791410847062,"version":"4.3.3"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>No-reflow phenomenon as a serious complication following percutaneous coronary intervention, deteriorates clinical outcomes. Intracoronary (IC) Adenosine, seems to be a way to deal with it. One hundred four consecutive patients with ST-segment elevation myocardial infarction were randomized into two groups. Each group consisted of 52 patients who managed with two bolus doses of IC Adenosine (Adenosine group) or two bolus doses of IC normal saline (placebo group) administered before and after stenting. Thrombolysis in myocardial infarction (TIMI) grade flow, ST-segment resolution (STR) and post-procedural clinical outcomes were used as endpoints. IC adenosine led to lower rates of no-reflow based on TIMI grade flow scaling (15.4% vs. 44.3%; <jats:italic toggle=\"yes\">P<\/jats:italic>-value: 0.02). STR classified as complete, partial and no resolution was similar between two groups (<jats:italic toggle=\"yes\">P<\/jats:italic>-value: 0.748). Also, post-interventional clinical outcomes, including arrhythmia, left ventricular ejection fraction, hospitalization time, and 30 days mortality were similar between Adenosine and placebo groups.<\/jats:p>","DOI":"10.1097\/mca.0000000000000863","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T16:32:36Z","timestamp":1584117156000},"page":"527-529","source":"Crossref","is-referenced-by-count":11,"title":["Randomized trial of intracoronary adenosine as adjunctive therapy for prevention of the no-reflow phenomenon"],"prefix":"10.1097","volume":"31","author":[{"given":"Nima","family":"Naghshtabrizi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tehran University of Medical Science, Tehran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manijeh","family":"Sajedi","sequence":"additional","affiliation":[{"name":"School of Medicine, Hamadan University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behshad","family":"Naghshtabrizi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hamadan University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Mozayanimonfared","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hamadan University of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Ali Seif Rabiei","sequence":"additional","affiliation":[{"name":"Hamadan University of Medical Science, Hamadan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Kanonisabet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"R1-20230924","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury.","volume":"357","author":"Yellon","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-20230924","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1067\/mhj.2003.36","article-title":"No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention.","volume":"145","author":"Resnic","year":"2003","journal-title":"Am Heart J"},{"key":"R3-20230924","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0735-1097(00)00865-2","article-title":"Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.","volume":"36","author":"Morishima","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R4-20230924","doi-asserted-by":"crossref","first-page":"e1279","DOI":"10.1097\/MD.0000000000001279","article-title":"Efficacy of adenosine in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a PRISMA-compliant meta-analysis.","volume":"94","author":"Gao","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R5-20230924","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/eurheartj\/ehq492","article-title":"High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction.","volume":"32","author":"Desmet","year":"2011","journal-title":"Eur Heart J"},{"key":"R6-20230924","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCINTERVENTIONS.109.858977.109.858977","article-title":"Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.","volume":"2","author":"Fokkema","year":"2009","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:02:50Z","timestamp":1695538970000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000863","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,2]]}}}